Shaji Kumar

Shaji Kumar is one of the world's leading myeloma clinicians and has been central to developing and validating risk stratification models for smoldering multiple myeloma, including the Mayo 2018 and 20-2-20 models that guide clinical decision-making. He led the AQUILA trial evaluating daratumumab monotherapy in high-risk SMM, demonstrating a significant reduction in progression to active myeloma. His research encompasses novel drug combinations in active myeloma, minimal residual disease endpoints, and the biology of plasma cell disorders. He is a prolific contributor to ASH and ASCO myeloma educational programs.